Cingulate Inc. (CING) stock
CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
$4.64+0.08 (+1.75%)
Close on Nov 11, 2026Market cap $67.47MP/E –Yield –
Cingulate EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cingulate's EPS for the twelve months ending Jun 30, 2026 was -$3.68. For fiscal 2025 it was -$4.44. The highest annual figure on record is -$4.44 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.44 | – |
| FY2024 | Dec 31, 2024 | -$10.86 | – |
| FY2023 | Dec 31, 2023 | -$311.99 | – |
| FY2022 | Dec 31, 2022 | -$29.35 | – |
| FY2021 | Dec 31, 2021 | -$52.08 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.45 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.95 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.93 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.35 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.14 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.06 | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.21 | – |
| Q3 FY2023 | Sep 30, 2023 | -$72.60 | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.79 | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.08 | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.78 | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.72 | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.72 | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.26 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?